Rein Therapeutics RNTX
NASDAQ RNTX
$0.60 -0.02 (-3.90%)
As of: Oct 22, 2026 · 12:05 PM EDT

Rein Therapeutics (RNTX) EBIT Margin (2016)

Updated

Analysis

Rein Therapeutics (RNTX) EBIT Margin (2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,170.99 Bn 1,139.58 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 642.25 Bn 560.77 Bn 17.26 Bn 28.21%
3 AbbVie 502.08 Bn 475.19 Bn 12.70 Bn 37.86%
4 Merck 375.61 Bn 329.99 Bn 12.21 Bn -3.52%
5 Novartis Ag 302.76 Bn 266.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 268.66 Bn 242.35 Bn 12.86 Bn 20.57%
7 Amgen 241.98 Bn 197.38 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.37 Bn 167.57 Bn 6.22 Bn -133.21%
9 Pfizer 172.42 Bn 119.07 Bn 10.94 Bn 28.37%
10 Rein Therapeutics 40.28 Mn -3.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 -28,135.71%
API Access

Rein Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=RNTX&period=max&api_key=YOUR_API_KEY